Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs? J Clin Microbiol 2021 Mar 19;59(4)

Date

02/05/2021

Pubmed ID

33536296

Pubmed Central ID

PMC8092730

DOI

10.1128/JCM.00239-21

Scopus ID

2-s2.0-85102931996 (requires institutional sign-in at Scopus site)   2 Citations

Abstract

INTRODUCTIONWith numerous reported challenges to reporting MICs for vancomycin, clinical laboratories are attempting to identify accurate methods for MIC testing. However, the issues of poor reproducibility, accuracy, and clinical utility remain a challenge. In this Point-Counterpoint, Dr. Sara Revolinski discusses the pros of reporting MICs for vancomycin, while Dr. Christopher Doern argues for the use of caution.

Author List

Revolinski SL, Doern CD

Author

Sara L. Revolinski PharmD Adjunct Assistant Professor in the School of Pharmacy Administration department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Anti-Bacterial Agents
Humans
Laboratories
Methicillin-Resistant Staphylococcus aureus
Microbial Sensitivity Tests
Reproducibility of Results
Staphylococcal Infections
Vancomycin